Top-AMPK · Putting the top down on AMPK protein complex
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2022-08-01 → 2026-01-31
- Финансиране от ЕС
- 336 830 €
- Участници
- 4
- Схема
- HORIZON-TMA-MSCA-PF-GF
Линиите свързват координатора с партньорите.
Накратко на български
Протеинът AMPK, който регулира енергията в клетките, се анализира чрез масспектрометрия, за да се разберат неговите различни форми и комплекси. Това помага за по-точна диагностика и създаване на терапии, съобразени с молекулярния профил на всеки пациент.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Putting the top down on AMPK protein complex
Proteins rarely act alone. They form complexes, carry chemical modifications, and exist as multiple distinct proteoforms that together determine cellular function. Understanding this molecular complexity is a prerequisite for advancing personalized medicine, yet the tools to characterize it at sufficient resolution have only recently become available. Modern advances enable treatments increasingly tailored to an individual's molecular profile through greater precision in diagnosis, therapy, and prognosis. This approach aims to address disease causes rather than symptoms, with the potential for more targeted treatments with fewer side effects compared to conventional approaches. Achieving this requires analytical methods capable of resolving the full chemical heterogeneity of disease-relevant proteins, including modification states and proteoform distributions that previously remained inaccessible to conventional approaches. This project focused on the 5'-adenosine monophosphate-activated protein kinase (AMPK), known as the guardian of cellular energy, a central regulator of cellular energy metabolism operating through complex phosphorylation networks, and associated with metabolic disorders, cardiovascular diseases, and viral infections. Native top-down mass spectrometry was applied as the core methodology, allowing intact protein complexes to be analyzed while preserving non-covalent interactions and capturing the full proteoform landscape. The project brought together three complementary partners. The outgoing phase was carried out at the University of Wisconsin-Madison, chosen for its strong expertise in top-down proteomics, cardiac research, and kinase biology. The return phase was hosted at the University of Lübeck and CSSB Hamburg, providing a research environment centered on structural biology and native mass spectrometry. The non-academic placement at Bruker Daltonics connected the academic research directly to mass spectrometry instrument development, enabling knowledge transfer in both directions between fundamental research and industrial application. The broader objective was to establish a methodology applicable beyond AMPK, contributing to the molecular characterization of disease-relevant kinase complexes and illustrating how fundamental research in structural proteomics can inform future clinical development.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The 5' adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of cell energy metabolism. AMPK (dys)regulation has been connected to metabolomic disease, conditions of the heart and viral infections. AMPK is fine-tuned through its structural features, which are dependent on mRNA isoform splicing, protein complexation, post-translational modification (PTM), and allosteric activation . AMPK’s diverse regulatory role is deeply connected to its post-translational modifications (43 known phosphorylation and 36 known other PTM sites). The result of this structural diversity is an extremely large combinatorial space of (1) unique covalently modified α-β-γ isoforms, the proteoforms, and (2) their unique non-covalent assemblies, the complex species. However, the structural diversity of AMPK is not well understood. The goal of this project is to to study the modifications and endogenous diversity of AMPK proteoforms and complex species from a ""bird's eye view"", depicting and mapping in parallel existing complete length AMPK forms, using denatured and native Top-down Mass Spectrometry (TDMS). -Outgoing phase, Ying Ge Lab, University of Wisconsin-Madison (UWM) (M1-24): Recombinant AMPK complex to study coded proteoforms (O1-2) and establish a strategy for purification of endogenous AMPK (O3). -Incoming phase (M25-36), Charlotte Uetrecht Lab, University of Lübeck (UzL): Transfer learned technologies and map endogenous AMPK proteoforms in different tissues (O4). Design endogenous-ike AMPK proteoforms (O2). -Non-academic phase (M37-42) Bruker Daltonics GmbH (BRUKER): Close gaps in data acquisition and get more out of AMPK with next-gen MS instruments (O2).The aspired methodology and results will be important for the identification of AMPK biomarkers and, ultimately, for the advancement of precision medicine, where treatment is tailored for the individual molecular setup of a patient subgroup such as in metabolomic or heart disease.""
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITAET zu LUEBECK · LubeckКоординаторГермания
- BRUKER DALTONICS GMBH & CO KG · BremenГермания
- THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM · MADISON WIСъединени щати
- UNIVERSITAET SIEGEN · SiegenГермания
Връзки
- Виж в CORDIS
- DOI: 10.3030/101068151
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50cebe5c6&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5284fbfb4&appId=PPGMS
Данни: CORDIS, © Европейски съюз
